|
BMI <30 kg/m2
|
BMI ≥30 kg/m2
|
Continuous Use
Celecoxib
200 mg qd
n=209 |
Intermittent Use
Celecoxib
200 mg qd
n=205 |
p Value |
Continuous Use
Celecoxib
200 mg qd
n=222 |
Intermittent Use
Celecoxib
200 mg qd
n=222 |
p Value |
ITT Population |
Total WOMAC score, LSM (SE) |
1.33 (1.03) |
4.85 (1.03) |
0.016 |
1.84 (0.98) |
5.12 (0.99) |
0.019 |
95% CI |
(-0.69 to 3.35) |
(2.83 to 6.87) |
|
(-0.08 to 3.77) |
(3.18 to 7.06) |
|
WOMAC pain subscale, LSM (SE) |
0.32 (0.23) |
1.05 (0.23) |
0.024 |
0.40 (0.21) |
1.31 (0.21) |
0.002 |
95% CI |
(-0.13 to 0.77) |
(0.60 to 1.50) |
|
(-0.01 to 0.81) |
(0.90 to 1.73) |
|
WOMAC stiffness subscale, LSM (SE) |
0.10 (0.10) |
0.42 (0.10) |
0.019 |
0.13 (0.10) |
0.38 (0.10) |
0.075 |
95% CI |
(-0.10 to 0.29) |
(0.23 to 0.62) |
|
(-0.06 to 0.32) |
(0.19 to 0.57) |
|
WOMAC physical function subscale,
LSM (SE) |
0.89 (0.74) |
3.40 (0.74) |
0.017 |
1.36 (0.71) |
3.45 (0.71) |
0.038 |
95% CI |
(-0.57 to 2.34) |
(1.95 to 4.86) |
|
(-0.04 to 2.75) |
(2.05 to 4.85) |
|
FmITT |
Total WOMAC score, LSM (SE) |
-0.15 (1.18) |
2.40 (1.28) |
0.145 |
-0.13 (1.15) |
3.89 (1.17) |
0.015 |
95% CI |
(-2.47 to 2.17) |
(-0.12 to 4.91) |
|
(-2.38 to 2.13) |
(1.59 to 6.18) |
|
WOMAC pain subscale, LSM (SE) |
0.07 (0.26) |
0.48 (0.29) |
0.292 |
-0.00 (0.24) |
1.12 (0.25) |
0.001 |
95% CI |
(-0.45 to 0.58) |
(-0.09 to 1.04) |
|
(-0.48 to 0.48) |
(0.63 to 1.61) |
|
WOMAC stiffness subscale, LSM (SE) |
0.01 (0.11) |
0.24 (0.12) |
0.164 |
-0.00 (0.11) |
0.23 (0.12) |
0.162 |
95% CI |
(-0.20 to 0.23) |
(0.00 to 0.47) |
|
(-0.22 to 0.23) |
(0.01 to 0.46) |
|
WOMAC physical function subscale,
LSM (SE) |
-0.25 (0.85) |
1.71 (0.92) |
0.117 |
-0.09 (0.83) |
2.55 (0.84) |
0.026 |
95% CI |
(-1.92 to 1.41) |
(-0.10 to 3.52) |
|
(-1.71 to 1.54) |
(0.90 to 4.21) |
|
BMI, body mass index; CI, confidence interval; ITT, intent-to-treat; FmITT: flare-modified ITT; qd, daily; SE, standard error; WOMAC, Western Ontario and McMaster
Universities Arthritis Index.